5 Key Takeaways

• 1

  Traditional pathology often struggles with cancers of unknown primary (CUP) and diagnostically ambiguous tumors, leading to inconclusive results.

• 2

  Molecular testing can enhance tumor origin detection and identify actionable biomarkers, guiding treatment decisions in challenging cases.

• 3

  CUPs are particularly difficult to classify due to broad differential diagnoses and limitations of morphology and immunohistochemistry.

• 4

  Approximately one-third of patients undergoing genomic profiling have actionable biomarkers, with many CUP patients eligible for targeted therapies.

• 5

  Next-generation sequencing can differentiate between separate primary tumors and metastases, which is crucial for appropriate clinical management.